XOMA Royalty Corporation Stock Price, News & Analysis

XOMA Royalty (Nasdaq: XOMA) announced it has completed the acquisition of Mural Oncology (Nasdaq: MURA) by way of an Irish High Court sanctioned scheme of arrangement.

Mural shareholders received $2.035 cash per share as the consideration. The scheme was sanctioned by the Irish High Court on December 3, 2025 and became effective on December 5, 2025 upon delivery of the court order to the Irish Companies Registration Office.

Prior to trading on December 5, 2025, Mural shares will cease trading on Nasdaq and Mural intends to seek prompt delisting and deregistration under the Securities Exchange Act of 1934.

XOMA Royalty (Nasdaq: XOMA) announced on Nov 21, 2025 it has completed its acquisition of all outstanding common shares of LAVA Therapeutics (Nasdaq: LVTX). LAVA shareholders received $1.04 cash per share plus a non-transferable contingent value right (CVR) that may pay up to ~$0.23 per CVR depending on post-closing liability determinations. Approximately 23,956,708 shares (91.1%) were tendered by the final expiration date; XOMA Royalty acquired 100% of LAVA’s successor via a corporate reorganization. Trading of LAVA shares was suspended before Nov 21, 2025, and LAVA intends to delist and deregister its shares.

Deal highlights: two partnered bispecific antibody programs with Johnson & Johnson and Pfizer; cash consideration and CVR structure for shareholders.

XOMA Royalty (NASDAQ: XOMA) reported third-quarter and year-to-date 2025 results on November 12, 2025, highlighting portfolio-building acquisitions, partner clinical readouts, and cash receipts. In the first nine months of 2025 XOMA received $43.9M from partners ($30.3M royalties, $13.6M milestones/fees) and $14.3M in Q3 royalties. Income and revenue were $9.4M (Q3) and $38.4M (YTD). Net income was $14.1M (Q3) and $25.6M (YTD). Cash and equivalents totaled $130.6M on September 30, 2025, including $85.4M restricted cash. Recent acquisitions include Turnstone, HilleVax, announced LAVA and Mural deals; several partner Phase 3 readouts are anticipated through mid-2026.

XOMA Royalty (Nasdaq: XOMA) and LAVA Therapeutics (Nasdaq: LVTX) amended their share purchase agreement on October 17, 2025.

Under the Amendment, tendering LAVA shareholders will receive an initial cash amount of $1.04 per share plus a non-transferable CVR that preserves rights to 75% of net proceeds from partnered assets and unpartnered program exits, and a new contingent right of up to $0.23 per CVR depending on final liability determinations. LAVA’s minimum net-cash closing condition was reduced to $24.5 million (from $31.5 million). The Offer deadline extended to Nov 12, 2025 and closing is expected in Q4 2025, subject to tender thresholds and shareholder approvals.

XOMA Royalty (NASDAQ: XOMA) and LAVA Therapeutics (Nasdaq: LVTX) extended the expiration of their tender offer to acquire all outstanding LAVA shares until one minute after 11:59 p.m. ET on October 17, 2025. The Offer pays a cash amount (per the Purchase Agreement) plus a non-transferable CVR per share granting holders 75% of net proceeds from LAVA’s two partnered assets and 75% of net proceeds from any out-license or sale of unpartnered programs. Closing is expected in Q4 2025, subject to conditions including at least 80% (or 75%) tendered shares, shareholder approvals, a minimum cash balance at closing, and other customary conditions. LAVA shareholders have signed support agreements; a shareholder meeting is planned before early November 2025.

XOMA Royalty Corporation (NASDAQ: XOMA) has declared quarterly cash dividends for its preferred stockholders. The company will distribute dividends to two classes of preferred shares:

- Holders of 8.625% Series A Preferred Stock (NASDAQ: XOMAP) will receive $0.53906 per share
- Holders of 8.375% Series B Preferred Stock (NASDAQ: XOMAO) will receive $0.52344 per depositary share

Both dividends are scheduled for payment on October 15, 2025, to shareholders of record as of October 3, 2025.

XOMA Royalty (NASDAQ: XOMA) has successfully completed its tender offer to acquire HilleVax (NASDAQ: HLVX). The acquisition terms included $1.95 per share in cash plus one non-tradeable contingent value right (CVR).

The tender offer expired on September 15, 2025, with 39,214,689 shares validly tendered, representing approximately 77.48% of HilleVax's outstanding shares. Following the merger completion, HilleVax became a wholly owned subsidiary of XOMA Royalty. HilleVax shares will cease trading on Nasdaq as of September 17, 2025, and will be delisted and deregistered.

XOMA Royalty Corporation (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's leadership team, including CEO Owen Hughes and CIO Brad Sitko, will deliver a company update presentation on Monday, September 8, 2025, at 9:00 AM ET.

Investors can access the presentation through a webcast link or via the investor relations section of XOMA's website at www.xoma.com.

XOMA Royalty (NASDAQ:XOMA) has announced its subsidiary XRA 5 Corp. will acquire Mural Oncology (NASDAQ:MURA) in an all-cash transaction valued at approximately $36.2 million. Under the agreement, Mural shareholders will receive a base price of $2.035 per share, with potential for an additional $0.205 per share based on Mural's closing net cash position.

The base offer represents a 13.1% premium to Mural's closing price of $1.80 on August 19, 2025, and a 97.6% premium to its undisturbed price of $1.03 on April 14, 2025. The acquisition, recommended by Mural's board, follows a strategic review process and is expected to close by the end of 2025, subject to shareholder and regulatory approvals.